Mycoprotein and Pea Protein Blend and Muscle Protein Synthetic Response

Muscle Protein Synthesis Clinical Trial

— BPM  

Official title:

Comparing Postprandial Muscle Protein Synthesis Rates Following the Consumption of Mycoprotein, Pea Protein and a Mycoprotein/Pea Protein Blend in Resistance Trained Individuals

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04894747
• Other study ID #: 200325_B_04UOE
• Status: Completed
• Phase: N/A
• Start date: May 1, 2021
• Est. completion date: June 15, 2022

Study information

• Verified date: March 2023
• Source: University of Exeter
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Dietary protein is vital for the preservation of health and optimal adaptation to training. Plant proteins are considered inferior to animal proteins with respect to their ability to stimulate an acute muscle building response and therefore support long-term muscle reconditioning. Pea protein is a highly commercially available plant proteins source (available as supplements, food ingredients etc.), yet there is no research investigating its ability to stimulate a muscle building response. The investigators aim to assess the effect of consuming pea protein on muscle protein synthesis rates and compare these results to mycoprotein, a source known to elicit a robust anabolic response.

Pea protein is lower in some of the essential amino acids, namely methionine, which could mean it is less effective compared with mycoprotein which has a more complete amino acid profile. So in addition to comparing pea with mycoprotein, the investigators also want to compare to a blend of pea and mycoprotein to see if replenishing the amino acid content in pea 'rescues' the anabolic response.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 33
• Est. completion date: June 15, 2022
• Est. primary completion date: June 15, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• BMI between 18 and 30

• Resistance trained

Exclusion Criteria:

• Any metabolic impairment

• Smoking

• Use of over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices).

• A personal family history of epilepsy, seizures or schizophrenia.

• Allergic to Quorn/mycoprotein/edible fungi/environmental mould products.

• Any motor disorder.

Related Conditions & MeSH terms

• Muscle Protein Synthesis

Intervention

Dietary Supplement:
• Bolus ingestion of protein
Ingestion of 25g of protein

Locations

Country	Name	City	State
United Kingdom	University of Exeter	Exeter

Sponsors (2)

Lead Sponsor	Collaborator
University of Exeter	Quorn

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Muscle protein synthesis	The rate of synthesis of new muscle protein (Fractional synthetic rate %/h)	8.5 hours
Secondary	Plasma amino acid kinetics	The appearance of amino acids from the protein drink in the circulation.	8.5 hours
Secondary	Serum insulin concentrations	Basal and postprandial concentrations of serum insulin	8.5 hours
Secondary	Translocation of mTOR via immunohistochemistry	Locality of mTOR within the muscle cell	8.5 hours
Secondary	mTOR phosphorylation via ATP kinase assay	The amount of mTOR that has been activated in the muscle cell	8.5 hours